Tavalisse 100 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FZ0P7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,439
Award facts
- Contract value 100% obligated
- $10,439.07 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,439.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Tavalisse 100 mg on January 6, 2026, with a completion date of January 28, 2026. This award represents a non-competitive delivery order placed under AmerisourceBergen's parent company Cencora, Inc.'s existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. The IDC serves as the primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal military and veteran healthcare systems.
Tavalisse (fostamatinib) is a spleen tyrosine kinase inhibitor indicated for the treatment of immune thrombocytopenia, a condition characterized by low platelet counts. This delivery order fulfills immediate pharmaceutical supply needs for the military health system and reflects the Defense Logistics Agency's reliance on established prime vendor relationships to efficiently procure specialized medications for military treatment facilities and other federal health programs. No set-aside designation was applied to this award, indicating the contract was competitively awarded through the open IDC vehicle.
Quick answers
Who was awarded contract SPE2DR26FZ0P7?
SPE2DR26FZ0P7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FZ0P7 worth?
The government has obligated $10,439 on SPE2DR26FZ0P7.
Is contract SPE2DR26FZ0P7 an order under another contract?
Yes. SPE2DR26FZ0P7 is a delivery order under SPE2DR25D2018, an indefinite delivery contract.
Was contract SPE2DR26FZ0P7 competed?
The extent of competition for SPE2DR26FZ0P7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award